As part of the agreement, Chiesi will distribute the product in Europe, Turkey and former CIS countries including promoting the drug, identifying patients and handling reimbursements.
Kamada will receive milestone payments of $60m on achieving certain regulatory and sales targets, according to the agreement.
Kamada CEO David Tsur said the agreement is another evidence for the interest in the inhalation product in the global Alpha-1 industry, as well as among physicians and patients looking forward for the successful completion of the clinical trials.
"Chiesi is an ideal partner for Kamada for its specialty, large experience and impressive reputation in the respiratory market," Tsur added.
Chiesi president and chairman Alberto Chiesi said, "We are delighted to enter this strategic alliance on inhaled AAT as this product has the potential to change the life of thousands of patients, suffering from this life-threatening genetic disorder."
Chiesi CEO Ugo Di Francesco said, "We are glad to add Inhaled AAT to our already strong late stage pipeline as it represents a perfect fit with Chiesi strategy, being a special care product with Orphan Drug status targeting a respiratory disease, consolidating our leadership position in some key countries."
Kamada said drug may be the world’s first drug developed to treat patients suffering from genetic Alpha1-Antitrypsin Deficiency through inhalation.